Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for Cellebrite DI (CLBT) over the last 6 years, with Dec 2024 value amounting to $17.6 million.

  • Cellebrite DI's Change in Accured Expenses rose 110.41% to $11.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $31.4 million, marking a year-over-year increase of 190.97%. This contributed to the annual value of $17.6 million for FY2024, which is 2295.91% up from last year.
  • Cellebrite DI's Change in Accured Expenses amounted to $17.6 million in FY2024, which was up 2,295.91% from $734,000 recorded in FY2023.
  • In the past 5 years, Cellebrite DI's Change in Accured Expenses registered a high of $22.4 million during FY2020, and its lowest value of -$8.9 million during FY2022.
  • Its 3-year average for Change in Accured Expenses is $3.2 million, with a median of $734,000 in 2023.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first spiked by 14,308.23% in 2020, then tumbled by 273.35% in 2022.
  • Yearly analysis of 5 years shows Cellebrite DI's Change in Accured Expenses stood at $22.4 million in 2020, then slumped by 77.25% to $5.1 million in 2021, then crashed by 273.35% to -$8.9 million in 2022, then surged by 108.29% to $734,000 in 2023, then skyrocketed by 2,295.91% to $17.6 million in 2024.